Helping patients reclaim a life of possibility
As part of our September European Young Myeloma Patients Group (EYMPG) meeting on Induced Menopause and Sexual Health in young myeloma patients, Filipa Lopes has shared her personal experience of treatment induced menopause. She was diagnosed with myeloma at the age of 29 and hopes her story encourages other young patients to seek support and…
Myeloma is a form of blood cancer. At diagnosis, and at each relapse, myeloma patients are confronted with complex treatment and care decisions that may feel overwhelming. What are my options? What are the side effects? How will it affect my quality of life? The questions you have regarding your care choices are deeply personal…
Myeloma Patients Europe (MPE) is seeking research grant applications, for funding of up to 100k €, on a project exploring shared-decision making in myeloma. If you are interested, please read the information below and complete the following application form. Deadline for submission is 3 pm CET on Friday 5th of November 2021
As bortezomib, an anti-myeloma medicine, is licensed as both an intravenous (IV – through the vein via a drip) and subcutaneous medicine (through the skin, via an injection), the European Medicines Agency (EMA) recently conducted a survey to understand which method was most commonly used across Europe. They also asked about the location of administration…